Hepion Pharmaceuticals
HEPA0.04590.00% ( 0.0000 )
Hepion Pharmaceuticals (HEPA)
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases,...
- Open
- 0.0459
- High
- 0.0459
- Low
- 0.0459
- Prev. Close
- 0.0459
- Volume
- 9
- Turnover
- 0.41
- Avg Price
- 0.0450
- Bid/Ask Ratio
- --
- Amplitude
- 0.00%
- 52wk High
- 0.1100
- Volume Ratio
- 0.00
- Turnover Ratio
- 0.00%
Hepion Pharmaceuticals Analyst Rating
View MoreForecast & Rating
May 16, 2024Price forecast
$1500.003267873.86%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 10 at 06:50 PM
Hepion Pharmaceuticals director Gary S. Stetz II files initial beneficial ownership statement
- PUBT · Jul 8 at 03:30 PM
Hepion Pharmaceuticals director Danina Fisher files initial beneficial ownership statement
- PUBT · Jul 2 at 03:32 PM
Hepion Pharmaceuticals appoints Danina Fisher, Gary S. Stetz II to board
- PUBT · Jun 17 at 03:16 PM
Hepion Pharmaceuticals holds annual shareholder meeting, votes on director slate
- Earnings Watch · May 14 at 03:50 PM
Hepion Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0
- TradingView · May 1 at 04:36 PM
Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% Stake
